Vedolizumab is a humanized monoclonal antibody that targets the α4β7 integrin, a key molecule involved in mediating gastrointestinal (GI) inflammation by directing lymphocytes to the gut-associated lymphoid tissue (GALT). By selectively inhibiting α4β7 integrin, vedolizumab prevents the adhesion of lymphocytes to mucosal addressin cell adhesion molecule-1 (MAdCAM-1), thereby blocking lymphocyte trafficking into the intestinal mucosa. This mechanism allows for the treatment of chronic GI inflammatory conditions, such as ulcerative colitis and Crohn’s disease, without broadly suppressing systemic immune responses.
In both research and clinical settings, vedolizumab serves as a targeted therapeutic and pharmacodynamic biomarker, particularly in studying gut-specific immune regulation and lymphocyte migration. It is especially valuable in therapeutic drug monitoring (TDM), where it helps maintain appropriate serum levels for effective disease management and minimizes adverse effects. TDM applications include optimizing dosage regimens, assessing treatment efficacy, and ensuring patient compliance.
Additionally, vedolizumab is studied in relation to anti-drug antibodies (ADAs) that can emerge in some patients, potentially impacting its pharmacokinetics and therapeutic response. Understanding and monitoring these immunogenic responses is critical in both clinical trials and real-world treatment to personalize therapies and improve long-term outcomes in inflammatory bowel diseases.
This product is manufactured in Turkey by Matriks Biotek.